CK Regeon Information

CK Regeon Inc. is a biotech-based company founded in October, 2016 aiming to develop First-in-Class drugs addressing unmet medical needs. The company was established on the basis of the Transnational Research Center for Protein Function Control (TRCP/ ERC), a government-supported drug development institute, which has been directed by the CEO of CK Regeon Inc., Dr. Kang-Yell Choi, for more than 10 years. The excellence of their previous R&D achievements of his laboratory was proven by several times selections of the nationally honorary awards such as “National R&D Excellence of 100” and “excellent basic research 50”. He also successfully performed major national drug development projects such as “Korea Drug Development Fund” and “National OcoVentrue”. Currently, on the basis of the previous outcomes from TRCP, CK Regeon Inc. has been performing R&D for development of drugs targeting Wnt/β-catenin pathway related with regeneration. CK Regeon Inc. especially interested in the diseases suppressed regeneration in damaged and disease status tissues by suppression of the Wnt/β-catenin signaling. CK Regeon Inc. identified cytosolic overexpression of CXXC5, a negative feedback regulator of the Wnt/β-catenin signaling, as a major disease marker for the targeting diseases not only by usage of the disease model, but also by characterization of patient tissues. The aiming drug candidates revels therapeutic effects by restorative activation of the Wnt/β-catenin signaling followed by recovery of the tissue regeneration system. The drug candidates under the development by CK Regeon Inc. selectively function to the patients who overexpressed CXXC5, but not to healthy persons maintain low level of CXXC5 especially at cytosol. The targeting diseases include obesity, diabetes, and nan-alcoholic steatohepatitis (NASH), as well as the topically applicable drugs promoting hair growth and wound healing.